Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from GB Sciences, Inc.

< Previous 1 2 3 Next >
GB Sciences Announces Outstanding Results from Preclinical Study of Its Parkinson's Disease Formulations
GB Sciences, Inc. (OTCQB: GBLX) announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr.... 
Tickers GBLX
From PR Newswire
GB Sciences Announces the Sale of The Majority Interest in Nevada Cultivation Operations to Focus on Its First Two Cannabinoid-Based Medical Compounds for Parkinson's Disease and Neuropathic Pain
GB Sciences, Inc. (OTCQB: GBLX) announced the execution of a Binding Letter of Intent for the Sale of 75% of its membership interests in the Company's Las Vegas, Nevada cultivation and production... 
Tickers GBLX
From PR Newswire
GB Sciences Closes the Sale of GB Sciences Louisiana Cannabis Business to Wellcana Plus and Retains the Benefit of IP Developed Under GB Sciences Louisiana's Master Research and Development Agreement
GB Sciences, Inc. (OTCQB: GBLX) completed the sale on November 15, 2019 of its 50% membership interest in GB Sciences Louisiana, LLC to Wellcana Plus, LLC, an affiliate of Wellcana Group, LLC who owns... 
Tickers GBLX
From PR Newswire
The Closing Date of GB Sciences' Sale of GB Sciences Louisiana LLC Is Delayed
GB Sciences, Inc. (OTCQB: GBLX) announces a delay in the sale of GB Sciences Louisiana LLC. 
Tickers GBLX
From PR Newswire
GB Sciences Welcomes Esteemed Patent and Intellectual Property Attorney, Mr. Edmond DeFrank, to Its Board of Directors
GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce that on October 23rd Mr. Edmond DeFrank joined its Board of Directors, filling a vacant seat. Mr. DeFrank is an attorney in the cannabis sector... 
Tickers GBLX
From PR Newswire
GB Sciences' Chief Science Officer Featured on the Cover of the Marijuana Business Magazine
GB Sciences, Inc. (OTCQB: GBLX) is featured in the October 2019 edition of the Marijuana Business Magazine. This edition (https://mjbizmagazine.com/digital-issues/2019-09-Oct/) examines the evolution... 
Tickers GBLX
From PR Newswire
GB Sciences Sells Its Louisiana Medical Marijuana Business At A $32 Million Total Valuation
GB Sciences, Inc. (OTCQB: GBLX), on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. The stake will be purchased by Wellcana Plus... 
Tickers GBLX
From PR Newswire
U.S. Drug Enforcement Agency to Expand Cannabis Research: GB Sciences Submitted One of Thirty-Three Applications to Become a DEA-Registered Cannabis Supplier to U.S. Marijuana Researchers
GB Sciences, Inc. (OTCQB: GBLX) today announced that it has received notification from the U.S. Drug Enforcement Agency (DEA) that prior to making any decisions on the pending applications, the DEA... 
Tickers GBLX
From PR Newswire
GB Sciences Names Darin Carpenter as Executive Vice President of Cannabis Operations
GB Sciences, Inc. (OTCQB: GBLX) today announced the appointment to GB Sciences' executive team of Darin Carpenter as the company's new Executive Vice President for Operations and General Manager,... 
Tickers GBLX
From PR Newswire
GB Sciences Prepares To Launch New Products In Louisiana With Educational Seminars For Doctors And Pharmacists
GB Sciences, Inc. (OTCQB: GBLX) announced that its subsidiary GB Sciences Louisiana will hold a series of seminars in August, in partnership with state-approved medical cannabis pharmacies and the LSU... 
Tickers GBLX
From PR Newswire
History Made! GB Sciences Louisiana Announces Medical Cannabis Products Now for Sale for First Time in State History
GB Sciences Louisiana (OTCQB: GBLX) today announced that its medical cannabis products, developed in partnership with LSU AgCenter's Therapeutic Cannabis Program, are available for sale to qualified... 
Tickers GBLX
From PR Newswire
GB Sciences Files Novel Patent Application For Chronic Pain Treatments Based On Proprietary Cannabis-Derived Formulations
In the US, chronic pain represents an estimated health burden of between $560 and $650 billion dollars. 
Tickers GBLX
From PR Newswire
GB Sciences Obtains Exclusive License for Patented Oral Thin Film Technology Containing Cannabis and Hemp-Derived Ingredients
GB Sciences, Inc. (OTCQB:GBLX) today announced it has obtained an exclusive license to formulate, manufacture, and sell cannabis-infused oral thin films through its MME-licensed subsidiaries and... 
Tickers GBLX
From PR Newswire
GBS Global Biopharma and National Research Council of Canada Begin Preclinical Studies on Chronic-Neuropathic Pain Therapies
GBS Global Biopharma's proprietary neuropathic pain therapies are orally-delivered, time-released nanoparticles containing myrcene and other cannabinoid-based ingredients 
Tickers GBLX
From PR Newswire
GB Sciences Prepares to Triple Production Capabilities in Its Las Vegas Facility
Positioned to Increase Revenue by Approximately $5.6 Million 
Tickers GBLX
From PR Newswire
GB Sciences Louisiana Receives All Approvals and Announces the Opening of the Full Tissue Propagation Cannabis Cultivation at LSU Agricultural Center
Increases production and ensures a continuous supply of therapeutic cannabis for Louisiana patients. 
Tickers GBLX
From PR Newswire
Today: GB Sciences' Use of Controlled Cultivation, Product Formulations and Research Will Be Presented by Dr. Dominick Monaco at Cannabis Conference 2019, As Featured on Cover of Cannabis Business Tim
GB Sciences, Inc. (OTCQB: GBLX) announced that Dr. Dominick Monaco, GB Sciences' Director of Medical Formulations, will be a featured speaker at the Las Vegas Cannabis Conference TODAY, April 2, at... 
Tickers GBLX
From PR Newswire
GB Sciences Study Shows Nevada's Cannabis Strain Names Have No Correlation to Active Ingredients
What consumers see is not what they get: Study finds almost no chemical diversity in Nevada's cannabis varieties 
Tickers GBLX
From PR Newswire
In Case You Missed It: GB Sciences Approved For Full Operations In Main LSU AgCenter Production Facility
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. 
Tickers GBLX
From PR Newswire
Louisiana Agriculture Commissioner Approves GB Sciences To Begin Full Operations In Main LSU AgCenter Production Facility
With over five times the production capacity, main facility will allow for a perpetual harvest cycle, ensuring a continuous supply of therapeutic cannabis for patients throughout Louisiana. 
Tickers GBLX
From PR Newswire
GB Sciences Launches Global Expansion in Canada with GBS Global Biopharma, Inc.
GB Sciences, Inc. (OTCQB: GBLX) today launched a global expansion strategy with the formation of GBS Global Biopharma Inc. ("GBS Global"), a cannabinoid medicine company based in Canada. GBS Global... 
Tickers GBLX
From PR Newswire
GB Sciences Supports the Position of LSU AgCenter: Allegations Made by Commissioner Are Untrue
LSU AgCenter issued the following statement on Friday, March 8th. 
Tickers GBLX
From PR Newswire
GB Sciences Completes Harvest of First Cannabis Crop in Partnership with The Louisiana State University Agricultural Research Center
GB Sciences, Inc. (OTCQB: GBLX) announced the harvest of the first test cannabis crop in the company's nationally-recognized collaboration with Louisiana State University Agricultural Center. 
Tickers GBLX
From PR Newswire
GB Sciences and The Colorado Hemp Project Sell First Hemp Crop for $0.7 Million Dollars
Additionally, this first crop provides important seeds and genetics for future crops 
Tickers GBLX
From PR Newswire
Dr. Andrea Small-Howard, GB Sciences' Chief Science Officer, Introduces, "Unique Methods to Identify Strong Lead Compounds" at the International Cannabinoid Derived Pharmaceutical Summit
Dr. Small-Howard will elucidate GB Sciences' Natural Products-Based Approach to Drug Discovery and is a panelist for the "Welcome Panel Session: Bringing Together Industry and Academia". 
Tickers GBLX
From PR Newswire
GB Sciences and Louisiana State University Agricultural Center Enter a Joint Research and Development Agreement for the Production of Therapeutic Cannabis Targeting Severe Medical Conditions and Disea
GB Sciences, Inc. (OTCQB: GBLX) announces on November 19, 2018, the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, on behalf of the Louisiana State... 
Tickers GBLX
From PR Newswire
GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor
GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the... 
Tickers GBLX
From PR Newswire
GB Sciences Files First Of Its Kind Provisional Patent Application For The Treatment Of Neuropathic Pain Using Time-Released, Myrcene-Based Nanoparticles
GB Sciences, Inc. (OTCQB: GBLX) and the Universidad de Sevilla (USE) announce the filing of a provisional patent application on the creation of myrcene-containing nanoparticles for use in the treatment... 
Tickers GBLX
From PR Newswire
More From Meredith Patterson, GB Sciences' Brain Nurse, As She Examines the Workings of CBD
Curious about the medical properties of cannabis, Meredith Patterson RN, BSN, CRRN aka "the brain nurse", provides a "tour guide through the lobes" as she writes a series of popular science cannabis... 
Tickers GBLX
From PR Newswire
GB Sciences Expands into the Oklahoma Medical Cannabis Market
GB Sciences, Inc. (OTCQB: GBLX) is proud to announce that it has signed a binding letter of intent with 4EVERGRN, LLC in Oklahoma. This company has been awarded cultivation, processing and dispensary... 
Tickers GBLX
From PR Newswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.